JNJ
FY2026 Q2 · Calendar Q3 2026
Johnson & Johnson
Johnson & Johnson delivered a solid Q2 2026 with $25.3 billion in sales (5.6% operational growth) and a $400 million raise in full-year guidance to a $101.1 billion midpoint. EPS of $2.90 beat the $2.84 consensus by 2.1%. The quarter was anchored by strong uptake of newly launched products across both Innovative Medicine (ICOTYDE, INLEXZO, RYBREVANT) and MedTech (VARIPULSE, vision lenses), with oncology remaining a primary growth engine through DARZALEX, CARVYKTI, and TALVEY. Despite the beat and raise, shares declined 2.7% on the report session, partially reflecting MedTech cardiovascular headwinds and STELARA biosimilar erosion, before recovering 7.7% over the subsequent period. Management's confident tone and continued pipeline execution (Firefly Bio acquisition, OTTAVA robotics, milvexian readout) reinforce the trajectory toward double-digit growth by decade's end.
EPS surprise+2.1%
Market move-2.7%
